Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1100441/000119312519063391/d674465d10k.htm
March 2019
March 2019
March 2019
February 2019
February 2019
November 2018
November 2018
November 2018
September 2018
August 2018
Exhibit 99.1
Press Release
RTI Surgical® Announces Fourth Quarter and Full Year 2018 Results
Results in Line with Guidance Driven by Operational Excellence Initiatives and Growth in Spine and OEM Franchises
ALACHUA, Fla., February 28, 2019 RTI Surgical, Inc. (Nasdaq: RTIX), a global surgical implant company, reported operating results for the fourth quarter and full year of 2018.
Fourth Quarter 2018 Highlights:
| Revenue increased to $71.2 million |
| Net income of $2.1 million, inclusive of $1.0 million of net non-recurring expenses |
| Adjusted EBITDA of $7.7 million, or 11% of revenue |
Full Year 2018 Highlights:
| 2018 revenues increased to $280.9 million |
| Net loss of $3.4 million, inclusive of $11.0 million of net non-recurring expenses |
| Adjusted EBITDA of $33.7 million, or 12% of revenue |
| Provides 2019 revenue guidance |
Our fourth quarter and full year 2018 results demonstrate solid financial performance resulting from consistent progress across our key strategic initiatives, stated Camille Farhat, President and CEO. We believe the ongoing successful efforts to reduce complexity and drive operational excellence, including significant cost reduction efforts in tissue manufacturing, are providing the foundation to accelerate RTIs growth. In 2018, we returned OEM to growth and continued to transition customers to long-term partners signaling the strength of our relationships and importance of our products to our partners. Further, the definitive agreement to acquire Paradigm Spine, announced in November 2018 and anticipated to close in early March, will contribute to the formidable platform of differentiated spine implants we established in 2018.
Farhat continued, We believe our accomplishments in 2018 have provided an exceptionally strong foundation to support our performance in 2019 and beyond. Our investment in rebuilding the spine pipeline has revitalized our new product development efforts, which we anticipate will serve as a catalyst for organic growth starting in 2020. We will work to continue to reduce the complexity of our business and extend operational excellence throughout the Company to accelerate the growth trajectory of RTI. We expect our performance will be driven by the successful integration of Paradigm, disciplined R&D efforts and the continued exploration of acquisition opportunities. We are excited for the year ahead.
Fourth Quarter 2018
RTIs worldwide revenues for the fourth quarter of 2018 were $71.2 million, compared with $70.8 million during the same period in the prior year. Gross profit for the fourth quarter of 2018 was $38.7 million, or 54.4% of revenues, a significant increase compared to $36.3 million, or 51.2% of revenues, in the fourth quarter of 2017.
During the fourth quarter of 2018, RTI incurred non-recurring pre-tax charges to support the ongoing strategic transformation of the business. The Company incurred $2.2 million in
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1100441/000119312519063391/d674465d10k.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Rti Surgical, Inc..
Rti Surgical, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
Rating
Learn More![]()
The increase in total net other expense is primarily attributable to higher interest expense of $3.2 million in 2017 compared to $1.7 million in 2016 as a result of higher interest rate and average debt balance as compared to the year ended December 31, 2016, offset by a foreign currency exchange gain of $87,000 for the year ended December 31, 2017, compared to a foreign currency exchange loss of $132,000 for the year ended December 31, 2016, resulting from changes in the value of the U.S. dollar versus the Euro and the timing of payments on foreign currency liabilities.
The increase is primarily driven by the longer period receivables remain outstanding for contracts with customers where inventory is exclusively built with no alternative use to us, and where revenue is recognized over time under ASC 606.
Under the terms of the agreement, we will pay $100.0 million in cash and issue 10,729,614 shares of RTI common stock at closing, and revenue based earnout consideration of up to $150.0 million in a combination of cash and RTI common stock.
Under the terms of the agreement, we will pay $100.0 million in cash and issue 10,729,614 shares of RTI common stock at closing, and revenue based earnout consideration of up to $150.0 million in a combination of cash and RTI common stock.
Costs of processing and distribution was negatively impacted by an inventory write-off of $6.6 million related to decreased distributions of our map3 implant; $1.0 million as a result of writing-off certain obsolete quantities primarily of bone graft substitute inventory due to the rationalization of our international distribution infrastructure; purchase accounting step up adjustments to Zyga inventory of $0.6 million charged to costs of processing and distribution as inventory was sold for the impact of the inventory write-off.
Under the terms of the...Read more
Under the terms of the...Read more
For the contracts with upfront...Read more
At December 31, 2018, we...Read more
We are subject to certain...Read more
We are subject to certain...Read more
Reconciliations of each of these...Read more
Davol did not achieve certain...Read more
Potential events or changes in...Read more
We are required to maintain...Read more
We are required to maintain...Read more
Marketing, general and administrative expenses...Read more
The accounting policies which we...Read more
Inflation generally affects us by...Read more
Non-GAAP financial measures used by...Read more
On November 1, 2018, we...Read more
Under the Contract Manufacturing Agreement,...Read more
Under the amended agreement: 1)...Read more
As a result of the...Read more
Accordingly, the $8.0 million and...Read more
We may elect to convert...Read more
We may elect to convert...Read more
The initial borrowings made under...Read more
The initial borrowings made under...Read more
We believe these are significant...Read more
In addition, on November 1,...Read more
Marketing, general and administrative expenses...Read more
We use the method and...Read more
In general, the income approach...Read more
Effective August 3, 2017, our...Read more
The decrease was primarily due...Read more
Research and development expenses increased...Read more
The decrease was primarily due...Read more
Research and development expenses decreased...Read more
Cardiothoracic-On August 3, 2017, we...Read more
We provide allowances for returns...Read more
We are implementing a focused...Read more
Pursuant to the Amended and...Read more
Spine revenues increased primarily as...Read more
Sports revenues increased primarily as...Read more
Management removes the amount of...Read more
Marketing, general and administrative expenses...Read more
Asset impairment and abandonment costs,...Read more
Costs of processing and distribution...Read more
In consideration for Biomet?s exclusive...Read more
As of December 31, 2018,...Read more
As of December 31, 2018,...Read more
The valuation of goodwill and...Read more
Under the terms of this...Read more
Intangible Assets and Goodwill....Read more
The calculation of the tax...Read more
2018 Net change in valuation...Read more
Total Revenues-Our total revenues increased...Read more
International revenues increased $0.9 million,...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Rti Surgical, Inc. provided additional information to their SEC Filing as exhibits
Ticker: RTIX
CIK: 1100441
Form Type: 10-K Annual Report
Accession Number: 0001193125-19-063391
Submitted to the SEC: Tue Mar 05 2019 5:12:54 AM EST
Accepted by the SEC: Tue Mar 05 2019
Period: Monday, December 31, 2018
Industry: Orthopedic Prosthetic And Surgical Appliances And Supplies